Innate Pharma Quote - IPHA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.81

Bid

2.81

Offer

2.87

Volume

13,416,903

1.47 Day's Range 3.5107

0.00 52 Week Range 0.00

Market Cap

226.074M

Previous Close

1.55

Open

1.50

Last Trade

2.87

Last Trade Time

08:12:42

Financial Volume

US$ 31,633,640

VWAP

2.3577

Average Volume (3m)

Shares Outstanding

80,453,282

Dividend Yield

PE Ratio

-20.19

Earnings Per Share (EPS)

-0.09

Revenue

61.64M

Net Profit

-7.57M

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therap... Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.innate-pharma.com

Headquarters

Marseille, Bouches-du-rhone, Fra

Founded

Innate Pharma SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IPHA. The last closing price for Innate Pharma was US$1.55. Over the last year, Innate Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Innate Pharma currently has 80,453,282 shares in issue. The market capitalisation of Innate Pharma is US$124.70 million. Innate Pharma has a price to earnings ratio (PE ratio) of -20.19.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Regulatory News: Innate Pharma SA (Euronext Paris:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma et l’Institut d’Innovation pour le Lymphome Folliculaire (IFLI) annoncent un investissement jusqu’à 7,9 millions de dollars de l’IFLI pour soutenir le développement d’IPH6501 dans le lymphome folliculaire

Innate recevra 3 millions de dollars en paiement initial et jusqu’à 4,9 millions de dollars en tranches d’investissements conditionnelles de l’Institut d’Innovation pour le Lymphome Folliculaire...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PTPIPetros Pharmaceuticals Inc	US$ 0.45 (36.45%)	1.16M
JZXNJiuzi Holdings Inc	US$ 1.99 (11.17%)	527
IVPInspire Veterinary Partners Inc	US$ 0.1942 (8.67%)	9.99k
INAQInsight Acquisition Corporation	US$ 10.25 (7.89%)	280
CAPTCaptiVision Inc	US$ 0.7699 (6.86%)	100
BNOXBionomics Ltd	US$ 0.2921 (-9.59%)	190.81k
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 53.40 (-7.76%)	45.68k
SNESSenesTech Inc	US$ 3.71 (-6.31%)	6.42k
HSDTHelius Medical Technologies Inc	US$ 0.46 (-6.12%)	1.2k
GLEGlobal Engine Group Holding Ltd	US$ 2.31 (-6.10%)	360
SMCISuper Micro Computer Inc	US$ 34.8392 (-4.45%)	1.99M
AAPLApple Inc	US$ 247.95 (-0.07%)	1.36M
NVDANVIDIA Corporation	US$ 134.22 (-0.03%)	1.22M
PTPIPetros Pharmaceuticals Inc	US$ 0.45 (36.45%)	1.16M
MCHPMicrochip Technology Inc	US$ 59.9653 (0.08%)	964.47k